A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

Recruiting now · Phase 1

Conditions studied: Advanced Breast Cancer

In brief

This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.

Key facts

Study ID

NCT06638307

Run by

Stemline Therapeutics, Inc.

People needed

240

Starts

2024-10-25

Expected to finish

2029-10-23

Last updated by the study team

2026-08-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Highlands Oncology Group — Springdale, Arkansas, United States (enrolling)
• City of Hope — Duarte, California, United States (enrolling)
• UC San Diego Moores Cancer Center — La Jolla, California, United States (enrolling)
• Stanford Cancer Center — Palo Alto, California, United States (enrolling)
• UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California, United States (enrolling)
• UCLA Hematology Oncology - Parkside — Santa Monica, California, United States (enrolling)
• Yale Comprehensive Cancer Center — New Haven, Connecticut, United States (enrolling)
• Advent Health Orlando — Altamonte Springs, Florida, United States (enrolling)
• Sarah Cannon Research Institute at Florida Cancer Specialists — Orlando, Florida, United States (enrolling)
• Florida Cancer Specialists & Research Institute (FCS) - Sarasota — Sarasota, Florida, United States (enrolling)
• Moffitt Cancer Center — Tampa, Florida, United States (enrolling)
• Winship Cancer Institute, Emory University — Atlanta, Georgia, United States (enrolling)
• University of Illinois Hospital and Health Sciences System (Outpatient Cancer Center) — Chicago, Illinois, United States (enrolling)
• University of Chicago Medical Center — Chicago, Illinois, United States (enrolling)
• University of Iowa Health Care — Iowa City, Iowa, United States (enrolling)
• The University of Kansas Cancer Center — Fairway, Kansas, United States (enrolling)
• Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland, United States (enrolling)
• Massachusetts General Hospital Cancer Center — Boston, Massachusetts, United States (enrolling)
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States (enrolling)
• START Midwest - Oncology — Grand Rapids, Michigan, United States (enrolling)
• Mayo Clinic — Rochester, Minnesota, United States (enrolling)
• Astera Cancer Care — East Brunswick, New Jersey, United States (enrolling)
• Perlmutter Cancer Center - Sunset Park — Brooklyn, New York, United States (enrolling)
• Perlmutter Cancer Center at NYU Langone Hospital - Long Island — Mineola, New York, United States (enrolling)
• Laura & Isaac Perlmutter Cancer Center at NYU Langone Health — New York, New York, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.